Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet...
Staff
Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022
DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable...
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that...
BriaCell Secures License for a Promising Novel Anti-Cancer Agent
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Alpha Pro Tech, Ltd. Announces Second Quarter 2022 Financial Results
Record Quarterly Building Supply Segment Sales of $10.8 Million, Up 10.4% Net sales for the second quarter of 2022 were...
Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022
Company announcement – No. 31 / 2022 Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET)...
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Milestone Scientific Announces Distribution Agreement with Clinical Technology, Inc. for the CompuFlo® Epidural System
New distribution agreement follows adoption of CompuFlo® Epidural System at key hospitals, healthcare systems and pain management clinicsROSELAND, N.J., Aug....
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Clinical Trial Now Expands to Fifteen U.S. Trial SitesHOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX),...
Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary
DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on...
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA...
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day...
SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first...
WIMI Hologram Academy: VR-based Practical Teaching for Industrial Robotics Courses
HONG KONG, Aug. 04, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
IntelGenx to Report Second Quarter 2022 Financial Results on August 11, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, Aug. 04, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films,...
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives...
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarterCONSHOHOCKEN, Pa.,...
HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...